Shionogi Verifies Effectiveness of S-2367, Its Investigational Agent for Obesity Management.Tokyo, Japan, July 12, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Shionogi has obtained positive results from its current phase IIa trial of S-2367, its proprietary investigational agent for the treatment of obesity. S-2367 is a small molecule, oral, once-daily neuropeptide Y Neuropeptide Y (NPY) is a 36 amino acid peptide neurotransmitter found in the brain and autonomic nervous system. It augments the vasoconstrictor effects of noradrenergic neurons. (NPY NPY neuropeptide-Y. ) Y5 receptor antagonist discovered by Shionogi Research Laboratories. NPY is an orexigenic neurotransmitter neurotransmitter, chemical that transmits information across the junction (synapse) that separates one nerve cell (neuron) from another nerve cell or a muscle. Neurotransmitters are stored in the nerve cell's bulbous end (axon). involved in appetite, energy intake, and energy consumption. In the trial conducted in 20 facilities in the US, the company has confirmed that S-2367 can maintain and continue weight loss in patients who are treated with diet. Going forward, the company plans to announce the results in detail, in particular about secondary end-points and metabolic parameters in the near future. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion